Order Article Reprints

Wei JQ, Yuile A, Itchins M, Kong BY, Li BT, Pavlakis N, Chan DL, Clarke SJ. Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis. Biomedicines. 2023; 11(7):1827. https://doi.org/10.3390/biomedicines11071827

Wei, Joe Q., Alexander Yuile, Malinda Itchins, Benjamin Y. Kong, Bob T. Li, Nick Pavlakis, David L. Chan, and Stephen J. Clarke. 2023. "Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis" Biomedicines 11, no. 7: 1827. https://doi.org/10.3390/biomedicines11071827

Wei, J. Q., Yuile, A., Itchins, M., Kong, B. Y., Li, B. T., Pavlakis, N., Chan, D. L., & Clarke, S. J. (2023). Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis. Biomedicines, 11(7), 1827. https://doi.org/10.3390/biomedicines11071827